Bio-Rad Laboratories, Inc. (BIO) Stock Price & How to Invest

Bio-Rad Laboratories designs and sells laboratory instruments, consumables, and reagents across two segments. Life Science supplies tools for molecular biology, protein analysis, and genomics, including its droplet digital PCR (ddPCR) systems, real-time PCR, electrophoresis, imaging, and process chromatography products. Clinical Diagnostics sells the workflows routine hospital and reference labs rely on: quality-control and data-management systems, blood typing and immunohematology, diabetes monitoring, and specialty assays. Trailing revenue runs around $2.58 billion, and the business is known for recurring consumables attached to a large installed base of instruments.

The investment picture is unusual because Bio-Rad also owns roughly 28% of Sartorius, a German bioprocessing and lab-equipment company, and that stake (worth on the order of $5 billion) is valued at nearly the whole of Bio-Rad's own market capitalization. In May 2026 activist Elliott Investment Management disclosed positions in both Bio-Rad and Sartorius, arguing the market gives Bio-Rad little credit for its core operations and pushing to unlock value. Meanwhile the operating business is soft: 2026 guidance was cut, with a conflict in the Middle East hurting the blood-typing diagnostics franchise, even as digital PCR grows at a double-digit clip. The result is a stock where activism, capital allocation, and a volatile equity stake matter as much as instrument sales.

The 2026 outlook was cut, with currency-neutral revenue guided to roughly a 3% decline to modest growth and operating margin trimmed toward 10% to 12%. A Middle East conflict reduced first-quarter revenue and remains a headwind for the blood-typing diagnostics business, which drew a meaningful share of the segment from that region. Because the Sartorius stake dwarfs the operating business in value, Bio-Rad's stock and reported results are highly sensitive to that single holding, and reported GAAP earnings can swing to losses on non-cash marks. Instrument demand across life-science tools has been weak, and any activist campaign carries execution and timing uncertainty. Dual-class shares concentrate voting control with the founding family, which can limit outside influence over the pace of change.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Bio-Rad Laboratories, Inc.'s investor relations page or your broker.

• Revenue (TTM): ~$2.58B
• Q1 2026 revenue: ~$592M
• Q1 2026 non-GAAP EPS: ~$1.89
• Market cap: ~$8.5B
• Sartorius stake (~28%): ~$5B
• 2026 rev guide (cn): ~-3% to +0.5%

At roughly $309 per share and an $8.5 billion market cap, the market values Bio-Rad's Sartorius stake at close to its entire capitalization, implying it assigns little value to the operating business. Trailing earnings are volatile because non-cash marks on the Sartorius holding flow through GAAP results, so headline EPS and P/E can be misleading. The activist thesis rests on that gap between the sum of the parts and the traded value.

There are three common ways to get BIO exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic basket, so BIO sits alongside other stocks that express the same thesis.

Walnut takes the basket route. Describe a thesis where BIO fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

Bio-Rad is really two assets in one ticker: a steady but sluggish tools franchise plus a giant Sartorius stake, and the value case now hinges as much on activist-driven capital allocation as on the underlying instruments business.

Whether BIO is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is BIO a buy?, and where the stock could go from here in the BIO stock forecast.

For income investors, whether BIO pays a dividend and how the payout looks is covered in does BIO pay a dividend?